Nature Medicine has published results from Helus Pharma’s Phase 2a randomized, placebo-controlled clinical trial evaluating SPL026 in participants with moderate-to-severe major depressive disorder. The study met its primary endpoint, demonstrating statistically significant and clinically meaningful reductions in depressive symptoms at two weeks as measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with a mean difference of -7.35 points versus placebo.
The trial enrolled 34 participants (mean age 32.8 years, 29.4% female, predominantly white) who had experienced depression for an average of 10.5 years. Participants receiving a single 21.5 mg intravenous infusion of SPL026 (n=17) over 10 minutes, combined with supportive psychotherapy sessions, demonstrated significant reduction in MADRS score compared to placebo (n=17). Treatment effects were evident as early as one week (mean difference: -10.75) and response rates at Week 2 were 35% for SPL026 versus 12% for placebo, with remission rates of 29% versus 12%. During the open-label extension, the treatment effect was maintained for up to three months, with effects lasting up to six months in some participants. The treatment was generally well tolerated, with no treatment-related serious adverse events reported.
According to Dr. David Erritzoe from Imperial’s Department of Brain Sciences and lead investigator of the trial, a single dose of SPL026 is safe, effective, and durable, with treatment effects comparable to other promising interventional treatments often requiring much longer treatment sessions. This publication represents important validation of short-acting serotonergic agonists as a clinically meaningful approach in mental health treatments. Although Helus is not advancing intravenous SPL026 in its current form, the insights continue to inform Helus’s HLP004 development program for generalized anxiety disorder, with Phase 2 topline data expected in Q1 2026.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://menafn.com/1110751419/Nature-Medicine-Publishes-Helus-Pharmas-Randomized-Placebo-Controlled-Phase-2A-Trial-Of-SPL026-In-Major-Depressive-Disorder